Join our community of traders FOR FREE!

  • Learn
  • Improve yourself
  • Get Rewards
Learn More

Tech giant IBM and shopping mall owner Scentre Group are to tie-up with Australia’s top three banks to test blockchain technology, aimed at digitizing bank guarantees, Reuters reported earlier this week.

According to a statement by Australia and New Zealand Banking Group, Westpac Banking Corp and Commonwealth Bank of Australia, the partnership will seek to explore ways to move away from paper-based bank guarantees in order to reduce processing time and minimize the risk of fraud.

IBM shares closed higher for a third consecutive trading session in New York on Wednesday. It has also been the sharpest daily surge since July 1st. The stock went up 0.94% ($1.32) to $141.54, after touching an intraday high at $141.82, or a price level not seen since April 17th ($141.98).

Shares of International Business Machines have risen 24.52% so far in 2019 compared with a 19.51% gain for the benchmark index, S&P 500 (SPX).

In 2018, IBM’s stock went down 25.91%, thus, it underperformed the S&P 500, which registered a 6.24% loss.

The companies are testing a new blockchain-based platform on a group of retail property leasing clients as part of an 8-week pilot program.

”While the pilot is focused on retail property leasing, this technology has the potential to benefit many sectors and reduce the risk of fraud across billions of dollars guaranteed by the banks,” Didier Van Not, general manager corporate and institutional banking at Westpac Banking Corp, was quoted as saying by Reuters.

Analyst stock price forecast and recommendation

According to CNN Money, the 17 analysts, offering 12-month forecasts regarding IBM’s stock price, have a median target of $150.00, with a high estimate of $173.00 and a low estimate of $115.00. The median estimate represents a 5.98% upside compared to the closing price of $141.54 on July 3rd.

The same media also reported that at least 11 out of 20 surveyed investment analysts had rated IBM’s stock as “Hold”, while 6 – as “Buy”. On the other hand, 2 analysts had recommended selling the stock.

TradingPedia.com is a financial media specialized in providing daily news and education covering Forex, equities and commodities. Our academies for traders cover Forex, Price Action and Social Trading.

Related News

  • Spot Silver hits one-week high on dovish Fed remarksSpot Silver hits one-week high on dovish Fed remarks Spot Silver surged to a fresh one-week high of $51.76/oz. on Tuesday, as remarks by Federal Reserve policy makers renewed prospects of an interest rate cut next month.Fed Governor Christopher Waller said on Monday that the US job market […]
  • Sterling Rebounds as Dollar Softens, But Faces HeadwindsSterling Rebounds as Dollar Softens, But Faces Headwinds Key Moments GBP/USD recovers part of Friday’s losses but remains below the mid-1.3500 area in early Asian trading. Higher September Fed hike expectations and renewed US-Iran tensions continue to underpin the safe-haven USD. […]
  • Gold little changed on stimulus outlook, increased physical demandGold little changed on stimulus outlook, increased physical demand Gold was little changed on Friday as investors weighed the prospects of Fed tapering its $85 billion bond purchasing program within the end of the year against increased physical demand, spurred by low prices. Silver, platinum and palladium […]
  • US stock-index futures retreat before GDP, jobs dataUS stock-index futures retreat before GDP, jobs data U.S. stock-index futures declined, predicting the Dow Jones Industrial Average will fall from a record level, as investors focused on GDP data for guidance on how long the Federal Reserve will maintain stimulus.Futures on the Standard […]
  • Silver Holds Below Technical Ceiling; Sellers ControlSilver Holds Below Technical Ceiling; Sellers Control Key Moments Silver trades in a tight range just above $64.00 as the week begins, with traders cautious ahead of major central bank decisions. XAG/USD remains capped below the 4-hour 200-period SMA at $64.91 and the 38.2% […]
  • JPMorgan Upgrades Biogen on 2027 Pipeline CatalystsJPMorgan Upgrades Biogen on 2027 Pipeline Catalysts Key Moments JPMorgan raised its rating on Biogen to Overweight from Neutral and set a December 2027 price target of $300 per share. Analyst Chris Schott highlighted three key clinical readouts by 2027, led by felzartamab in […]